Improving medication adherence in alcohol dependence

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 14, 2006, Pages 23-29

  Pettinati, Helen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BISMUTH SALICYLATE; DISULFIRAM; FLUPHENAZINE; HALOPERIDOL; NALTREXONE; NEUROLEPTIC AGENT; PIPOTIAZINE; RISPERIDONE;

ALCOHOLISM; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; HUMAN; NAUSEA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; TREATMENT REFUSAL;

EID: 33846152898     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224
2. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? systematic review of randomized controlled trials. Arch Intern Med 2004;164:722-732
3. Namkoong K, Farren CK, O'Connor PG, et al. Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications. J Clin Psychiatry 1999;60:449-453
4. Feeney GF, Connor JP, Young RM, et al. Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programme. J Clin Pharm Ther 2001;26:73-79
5. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997;54: 737-742
6. Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-573
7. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997;54:1130-1135
8. Bouza C, Magro A, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-828
9. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256:1449-1455
10. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-593
11. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25:1634-1647
12. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996;13:35-39
13. Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35:176-187
14. Pettinati HM, Volpicelli JR, Pierce JD Jr, et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000;19:71-83
15. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310
16. Del Boca FK, Kranzler HR, Brown J, et al. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 1996;20:1412-1417
17. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000;24: 1542-1549
18. Pettinati HM, Monterosso J, Lipkin C, et al. Patient attitudes toward treatment predict attendance in clinical pharmacotherapy trials of alcohol and drug treatment. Am J Addict 2003;12:324-335
19. Volpicelli JR, Pettinati HM, McLellan AT, et al. Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. New York, NY: The Guilford Press; 2001
20. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl 2005;170-178. Copyright by Alcohol Research Documentation, Inc., Rutgers Center of Alcohol Studies, Piscataway, NJ 08854
21. Pettinati HM, Weiss RD, Miller WR, et al. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. US Dept Health Human Services; National Institute of Health. Bethesda, Md: National Institute on Alcohol Abuse and Alcoholism; 2004
22. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295: 2003-2017
23. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
24. del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 1975;16:32-36
25. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004;99:1382-1392
26. Jeste SD, Patterson TL, Palmer BW, et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizopnr Res 2003;63:49-58
27. Olfson M, Mechanic D, Hansell S, et al. Predicting medication non-compliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-222
28. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
29. Ferguson L, Ries R, Russo J. Barriers to identification and treatment of hazardous drinkers as assessed by urban/rural primary care doctors. J Addict Dis 2003;22:79-90
30. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299
31. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773
32. David AS, Adams C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Assess 2001;5:1-61
33. Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 2003;23:294-304
34. Garbutt JC. New therapeutic options for alcohol dependence: long-acting intramuscular formulations of naltrexone. J Clin Psychiatry 2006;67(suppl 14):30-34